Mon, Nov 24, 2014, 7:39 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

United Parcel Service, Inc. Message Board

e7navy1999 313 posts  |  Last Activity: 3 hours ago Member since: Jan 21, 2000
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • e7navy1999 e7navy1999 3 hours ago Flag

    did I see phase III starting?

    Sentiment: Strong Buy

  • e7navy1999 e7navy1999 3 hours ago Flag

    near 1-million traded. most everyone has a buy/strong buy rating

    Sentiment: Strong Buy

  • Reply to

    Part 1 Scientific Advisors

    by e7navy1999 5 hours ago
    e7navy1999 e7navy1999 4 hours ago Flag

    awesome

  • not sure why it will not post but our founder is still actively involved in ONVO

    Sentiment: Strong Buy

  • Keith Murphy, Chairman and Chief Executive Officer

    Mr. Murphy has 20 years of experience in biotechnology, including serving in Product Strategy and Director of Process Development roles at Amgen. He is a co-founder of Organovo and has been responsible for all company operations since 2007. His ten years at Amgen included four years as Global Operations Leader for the largest development program in Amgen’s history, Phase 3 osteoporosis/bone cancer drug denosumab. At Amgen, he also worked to develop several other novel formulation and device products. Prior to Amgen, he played a central role at Alkermes, Inc. on the development team for their first approved product, Nutropin (hGH) Depot. He holds a B.S. in chemical engineering from the Massachusetts Institute of Technology and is an alumnus of the UCLA Anderson School of Management. Mr. Murphy serves as Vice Chairman of the Alliance for Regenerative Medicine, comprised of over 120 member companies, patient advocacy foundations, venture capital firms, and academic research institutes focused on the advancement of regenerative medicine through engagement with government leaders and cooperative efforts.
    Barry Michaels, Corporate Secretary and Chief Financial Officer

    Mr. Michaels has more than 30 years of financial and general management experience in the medical device and biotechnology industries. He has served as CFO of three private and three publicly traded companies: Cardima, Inc. (NASDAQ), Lipid Sciences, Inc. (NASDAQ), IntraTherapeutics, Inc., VIA Medical, Inc., Webster Laboratories (now a division of J&J/Cordis known as Biosense-Webster), and ICN Biomedicals, Inc. (AMEX). He has also served as an independent consultant to medical device and biotechnology companies since 1997.

    Sentiment: Strong Buy

  • e7navy1999 by e7navy1999 Nov 23, 2014 10:42 AM Flag

    For $6.31 cents you can have the distinguished list of Scientific Advisers, Management Team and Board of Directors working for you.

    Sentiment: Strong Buy

  • e7navy1999 by e7navy1999 Nov 23, 2014 10:40 AM Flag

    Dr. K. Craig Kent, M.D. — University of Wisconsin

    Dr. Kent is the Chairman of the Department of Surgery at the University of Wisconsin School of Medicine and Public Health and previously served as Chief of the Division of Vascular Surgery at both Columbia University and Weill Cornell Medical College. Dr. Kent has authored or co-authored more than 300 manuscripts and chapters that have been published in peer-reviewed journals and textbooks on vascular disease. He is regularly invited to speak at local, national and international scientific meetings on a wide variety of vascular surgery topics. His NIH-funded basic science lab explores the mechanisms of failure for bypass grafts and angioplasty following vascular intervention. Dr. Kent served as the 2006–2007 president of the Society for Vascular Surgery. He was trained in general surgery at the University of California at San Francisco and completed his vascular surgery fellowship at Brigham and Women’s Hospital–Harvard Medical School, where he was awarded the prestigious annual E.J. Wylie Traveling Fellowship.

    Sentiment: Strong Buy

  • David Mooney, Ph.D. — Harvard University

    Prof. Mooney is a scientific author and a leader in the research of signaling mechanisms of tissue development. He studies the mechanisms by which chemical (for example, specific cell adhesion molecules) or mechanical signals (for example, cyclic strain) are sensed by cells and alter cells’ proliferation and specialization to either promote tissue growth or destruction. This work assists in the understanding of cell behavior post-processing by the organ printing technology. Dr. Mooney is the Pinkas Family Professor of Bioengineering at Harvard University, a member of the National Academy of Engineering, and holds a Ph.D. from the Massachusetts Institute of Technology.

    Sentiment: Strong Buy

  • e7navy1999 by e7navy1999 Nov 23, 2014 10:39 AM Flag

    Glenn D. Prestwich, Ph.D. — University of Utah

    Dr. Prestwich is Presidential Professor of Medicinal Chemistry and Special Presidential Assistant for Faculty Entrepreneurism at the University of Utah, where he leads the Entrepreneurial Faculty Scholars program. His university research includes the study of biomaterials for tissue repair and tissue engineering and biological reagents. He co-founded multiple companies, including Carbylan BioSurgery, Inc. (medical devices), Sentrx Animal Care, Inc. (veterinary wound care), and Glycosan BioSystems, Inc. (cell therapy and research tools). He received the Governor’s Medal for Science and Technology for 2006, the 1998 Paul Dawson Biotechnology Award and the 2008 Volwiler Research Award of the AACP, the 2010 University of Utah Distinguished Scholarly and Creative Research Award, and the 2010 “Rooster Prize” of the International Society for Hyaluronan Science.

    Sentiment: Strong Buy

  • e7navy1999 by e7navy1999 Nov 23, 2014 10:38 AM Flag

    Gordana Vunjak-Novakovic, Ph.D. — Columbia University

    Prof. Vunjak-Novakovic is the Mikati Foundation Professor of Biomedical Engineering and Medical Sciences at Columbia University, where she directs the Laboratory for Stem Cells and Tissue Engineering and the bioengineering arm of the Columbia Stem Cell Initiative. The focus of her research is on engineering functional human tissues for regenerative medicine and study of development and disease. Among her many recognitions, she is a Fellow of the American Institute for Medical and Biological Engineering, a Fellow of the Biomedical Engineering Society, a founding Fellow of the Tissue Engineering and Regenerative Medicine Society, and a member of the Academia Europaea, Serbian Academy of Sciences and Arts, and the National Academy of Engineering.

    Sentiment: Strong Buy

  • e7navy1999 by e7navy1999 Nov 23, 2014 10:34 AM Flag

    Michael Renard, Executive Vice President of Commercial Operations

    Mr. Renard has more than 29 years of recognized, revenue-generating experience in commercial operation, business development and sales and marketing for the life science industry. With Beckman Coulter, he held various positions in program management, business operations and business development. He most recently was the vice president of marketing for North America commercial operations where he was responsible for achieving $2 billion in revenue across 11 major product lines. Before Beckman Coulter, he was vice president and general manager in a development-stage incubator division of Sanofi, Inc. and director of corporate accounts at Kallestad Diagnostics. Mr. Renard holds an M.B.A from Rockhurst University and a B.A. in Biology and Chemistry from St. Olaf College.

    Sentiment: Strong Buy

  • e7navy1999 by e7navy1999 Nov 23, 2014 10:34 AM Flag

    Sharon Collins Presnell, Ph.D., Chief Technology Officer and Executive Vice President of Research & Development

    Dr. Presnell has more than 18 years of experience in the leadership of product-focused R&D. As an assistant professor at the University of North Carolina at Chapel Hill, Dr. Presnell’s research in liver and prostate biology and carcinogenesis produced cell- and tissue-based technologies that were outlicensed for industrial applications. She joined Becton Dickinson (BD) in 2001 and played a key role in the early discovery and development of BD’s Discovery Platform and FACSTM CAP tools for the optimization of in vitro culture environments and flow cytometry-based characterization of cells. In her role at BD, she grew and led a large multi-disciplinary team to establish feasibility for the Discovery Platform and FACS CAP in multiple therapeutic areas, including diabetes, and stewarded both technologies through revenue-generating commercial partnerships. Dr. Presnell joined Tengion, Inc. in 2007 as the Vice President of Regenerative Medicine Research, and was responsible for the discovery and early development of Tengion’s Neo-Kidney Augment™ technology, which MedTronic secured first rights to purchase in a 2011 deal. Dr. Presnell holds a Ph.D. in pathology from the Medical College of Virginia.

    Eric Michael David, M.D., J.D., Chief Strategy Officer

    Dr. David has more than 15 years of experience in biomedical research and product development. He played a critical role in the commercial translation of 3D bioprinting as a founder and early director of Organovo, Inc. Dr. David was most recently associate partner at the consultancy McKinsey & Company, where he served private equity, pharmaceutical, biotech, diagnostic, and medical device clients to support pipeline and R&D strategy, as well as market entry strategy. Prior to his time at McKinsey, Dr. David served as a freelance consultant to the Department of Health and Human Services in the use of genomic techn

    Sentiment: Strong Buy

  • e7navy1999 by e7navy1999 Nov 23, 2014 10:32 AM Flag

    Keith Murphy, Chairman and Chief Executive Officer

    Mr. Murphy has 20 years of experience in biotechnology, including serving in Product Strategy and Director of Process Development roles at Amgen. He is a co-founder of Organovo and has been responsible for all company operations since 2007. His ten years at Amgen included four years as Global Operations Leader for the largest development program in Amgen’s history, Phase 3 osteoporosis/bone cancer drug denosumab. At Amgen, he also worked to develop several other novel formulation and device products. Prior to Amgen, he played a central role at Alkermes, Inc. on the development team for their first approved product, Nutropin (hGH) Depot. He holds a B.S. in chemical engineering from the Massachusetts Institute of Technology and is an alumnus of the UCLA Anderson School of Management. Mr. Murphy serves as Vice Chairman of the Alliance for Regenerative Medicine, comprised of over 120 member companies, patient advocacy foundations, venture capital firms, and academic research institutes focused on the advancement of regenerative medicine through engagement with government leaders and cooperative efforts.
    Barry Michaels, Corporate Secretary and Chief Financial Officer

    Mr. Michaels has more than 30 years of financial and general management experience in the medical device and biotechnology industries. He has served as CFO of three private and three publicly traded companies: Cardima, Inc. (NASDAQ), Lipid Sciences, Inc. (NASDAQ), IntraTherapeutics, Inc., VIA Medical, Inc., Webster Laboratories (now a division of J&J/Cordis known as Biosense-Webster), and ICN Biomedicals, Inc. (AMEX). He has also served as an independent consultant to medical device and biotechnology companies since 1997.

    Sentiment: Strong Buy

  • e7navy1999 by e7navy1999 Nov 23, 2014 10:27 AM Flag

    Tamar D. Howson, M.S., M.B.A.
    Ms. Howson is a seasoned business development executive within the pharmaceutical industry. She currently serves as a corporate business development and strategy consultant to biopharmaceutical companies and she serves as a director at Idenix, Oxigene Pharmaceuticals, and Warner Chilcott. Previously, she was a member of the transaction advisory firm, JSB Partners. Prior to that, she was senior vice president of Corporate and Business Development at Lexicon. She was also senior vice president of Corporate and Business Development at Bristol Myers Squibb. Ms. Howson spent nine years at SmithKline Beecham, where where she was senior vice president and director of Worldwide Business and Corporate Development for SmithKline Beecham, and also managed SmithKline Beecham's venture capital fund, SR One. Ms. Howson holds an M.B.A. from Columbia University, a M.S. from City University of New York, and a B.S. in Chemical Engineering from the Technion, Israel.

    Richard A. Heyman, Ph.D.
    Dr. Heyman is an experienced life science executive who is currently CEO of Aragon Pharmaceuticals, which he co-founded in 2009. Previously, Dr. Heyman was Chief Scientific Officer at Kalypsys, Inc., where he conducted drug discovery in therapeutic areas such as metabolic diseases, pain, and inflammation. In 1999, he co-founded and served as Chief Scientific Officer of X-Ceptor Therapeutics, a company that developed compounds targeting nuclear receptors for the treatment of metabolic diseases. Before X-Ceptor, he was Vice President of Research at Ligand Pharmaceuticals and was project leader for multiple discovery programs, including the successful identification and development of Panretin® and Targretin®, retinoids approved by the FDA for the treatment of cancer.

    Sentiment: Strong Buy

  • e7navy1999 by e7navy1999 Nov 23, 2014 10:26 AM Flag

    Keith Murphy, Chairman and Chief Executive Officer
    Mr. Murphy has 20 years of experience in biotechnology, including serving in Product Strategy and Director of Process Development roles at Amgen. He is a co-founder of Organovo and has been responsible for all company operations since 2007. His ten years at Amgen included four years as Global Operations Leader for the largest development program in Amgen’s history, Phase 3 osteoporosis/bone cancer drug denosumab. At Amgen, he also worked to develop several other novel formulation and device products. Prior to Amgen, he played a central role at Alkermes, Inc. on the development team for their first approved product, Nutropin (hGH) Depot. He holds a B.S. in chemical engineering from the Massachusetts Institute of Technology
    Robert Baltera, Jr., M.S., M.B.A. Mr. Baltera is a seasoned pharmaceutical industry executive, who acquired a wealth of business and product management experience during 17 years with biotech pioneer Amgen. In his recent role as CEO of Amira Pharmaceuticals, he led the company to acquisition by Bristol-Meyers Squibb Company.
    James T. Glover, M.B.A., C.P.A. Mr. Glover, our audit committee chairman, was formerly Senior Vice President and Chief Financial Officer of Beckman Coulter, Inc., and was also Senior Vice President of Operations and Chief Financial Officer of Anadys Pharmaceuticals, Inc, a publicly traded pharmaceutical company later acquired by Roche.

    Sentiment: Strong Buy

  • Reply to

    Killin it..

    by alidawawala Nov 21, 2014 9:37 AM
    e7navy1999 e7navy1999 Nov 21, 2014 10:50 AM Flag

    ur certainly in a better position then me, regardless I am long haul so the ups and downs do not matter one bit

    Sentiment: Strong Buy

  • Reply to

    FDA

    by e7navy1999 Nov 21, 2014 10:00 AM
    e7navy1999 e7navy1999 Nov 21, 2014 10:41 AM Flag

    ???? assays are printed liver cells. The 3D assay responds exactly the way a real liver in the human body responds to toxins. Roche already proved it with their KOL study

    Sentiment: Strong Buy

  • Reply to

    FDA

    by e7navy1999 Nov 21, 2014 10:00 AM
    e7navy1999 e7navy1999 Nov 21, 2014 10:06 AM Flag

    protect end user

  • e7navy1999 by e7navy1999 Nov 21, 2014 10:00 AM Flag

    What will ONVO be worth when the FDA comes out and makes ONVO 3D assay toxicology testing mandatory for all new drugs coming to market?

    Sentiment: Strong Buy

  • Reply to

    I'M OUT!!!

    by johnj93 Nov 10, 2014 11:39 AM
    e7navy1999 e7navy1999 Nov 21, 2014 9:54 AM Flag

    Wall Street posted expectations of a 10% move upward in energy.

    Sentiment: Strong Buy

UPS
107.26-0.09(-0.08%)Nov 24 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.